兴齐眼药：伏立康唑滴眼液II期临床试验首例受试者入组，适应症为真菌性角膜炎

Core Viewpoint - The company has initiated the Phase II clinical trial for Voriconazole eye drops, targeting fungal keratitis, a common and severe eye disease in China [1] Group 1: Company Developments - On August 12, the company announced the enrollment of the first subject in the Phase II clinical trial for Voriconazole eye drops [1] - Voriconazole is a new generation triazole antifungal with a broad antibacterial spectrum, low toxicity, and strong antibacterial efficacy [1] - The Phase II clinical trial is a randomized, positive-controlled, multi-center exploratory study aimed at assessing the efficacy and safety of Voriconazole eye drops in subjects with fungal keratitis [1] Group 2: Industry Context - Fungal keratitis is a common cause of blindness in China, characterized by high incidence, difficult clinical diagnosis, long treatment cycles, and a tendency to recur, causing significant patient suffering [1] - As of the announcement date, there are no approved Voriconazole eye drops listed on the National Medical Products Administration website [1]